Skip to main content
Premium Trial:

Request an Annual Quote

Matthew Pando, John Jaskowiak, Philippe Rousseau, Bruno Tocque, Douglas Amorese

Premium
ExonHit Therapeutics said last week that Matthew Pando and John Jaskowiak will join the company’s management board, and Philippe Rousseau will become president of the board until the company appoints a new CEO. Rousseau has been chief financial officer at ExonHit since 2002 and has been a member of its management board since 2004. The firm’s previous CEO and co-founder Bruno Tocque will remain with ExonHit in a consulting position.
 
Jaskowiak started with the company in 2006, and was recently appointed head of Molecular Diagnostics and Genomic Services. Pando came to the company in 2002, and recently was named head of its Therapeutics Unit.
 

 
Douglas Amorese has been named vice president of research and development at NuGen Technologies, the firm said this week.  
 
Amorese was most recently director of R&D in Agilent Technologies’ genomics group. He has also held positions at Life Technologies and DuPont.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.